000			02801nam a2200289Ia 4500
999			_c37381 _d37381
001			37381
003			DR-UNIBE
005			20201017090313.0
008			201017b2006 -us||||| |||| 00| 0 eng d
040			_cBIBLIOTECA UNIBE _aBIBLIOTECA UNIBE
041			_aspa
090			_aF- 3052
245	0		_aThe endocannabinoid system and regulation of energy metabolism : define understand Acknowledge Highlight Review / _ceditors: Jorge Plutzky, Stephen C. Woods.
260	4		_aBoston : _bSanofi Aventis, _c2006
300	4		_a28 p. : il.
504	4		_aIncludes bibliographical references (p. 27 - 28 )
520	4		_aThe endocannabinoid system (ECS) consists of two receptors (CB(1) and CB(2)), several endogenous ligands (primarily anandamide and 2-AG), and over a dozen ligand-metabolizing enzymes. The ECS has deep phylogenetic roots and regulates many aspects of embryological development and homeostasis, including neuroprotection and neural plasticity, immunity and inflammation, apoptosis and carcinogenesis, pain and emotional memory, and the focus of this review: hunger, feeding, and metabolism. The ECS controls energy balance and lipid metabolism centrally (in the hypothalamus and mesolimbic pathways) and peripherally (in adipocytes and pancreatic islet cells), acting through numerous anorexigenic and orexigenic pathways (e.g., ghrelin, leptin, orexin, adiponectin, endogenous opioids, and corticotropin-releasing hormone). Obesity leads to excessive endocannabinoid production by adipocytes, which drives CB(1) in a feed-forward dysfunction. Phylogenetic research suggests the genes for endocannabinoid enzymes, especially DAGLalpha and NAPE-PLD, may harbor mildly deleterious alleles that express disease-related phenotypes. Several CB(1) inverse agonists have been developed for the treatment of obesity, including rimonabant, taranabant, and surinabant. These drugs are efficacious at reducing food intake as well as abdominal adiposity and cardiometabolic risk factors. However, given the myriad beneficial roles of the ECS, it should be no surprise that systemic CB(1) blockade induces various adverse effects. Alternatives to systemic blockade include CB(1) partial agonists, pleiotropic drugs, peripherally restricted antagonists, allosteric antagonists, and endocannabinoid ligand modulation. The ECS offers several discrete targets for the management of obesity and its associated cardiometabolic sequelae
650			_aTrastornos de la Nutrición _97422
650			_aDesórdenes del Metabolismo _94876
650			_areceptores cannabinoides _950547
650			_aMetabolismo _97462
650			_ametabolismo energético _950548
700	4	0	_aPlutzky, J. (Jorge) _950549
700	4	0	_aWoods, Stephen C. _950550
710		2	_asanofi aventis (Firm) _950551
942			_2ddc _cMX